Circulating stem cell vary with NYHA stage in heart failure patients
We have investigated the blood levels of sub‐classes of stem cells (SCs) [mesenchymal stem cells (MSCs), haematopoietic stem cells (HSCs), endothelial progenitor cells/circulating endothelial cells (EPCs/CECs) and tissue‐committed stem cells (TCSCs)] in heart failure (HF) patients at different stage...
Gespeichert in:
| Veröffentlicht in: | Journal of cellular and molecular medicine 2011-08, Vol.15 (8), p.1726-1736 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1736 |
|---|---|
| container_issue | 8 |
| container_start_page | 1726 |
| container_title | Journal of cellular and molecular medicine |
| container_volume | 15 |
| creator | Fortini, Cinzia Toffoletto, Barbara Fucili, Alessandro Puppato, Elisa Olivares, Adriana Beltrami, Antonio Paolo Fiorelli, Valeria Bergamin, Natascha Cesselli, Daniela Morelli, Cristina Francolini, Gloria Ferrari, Roberto Beltrami, Carlo Alberto |
| description | We have investigated the blood levels of sub‐classes of stem cells (SCs) [mesenchymal stem cells (MSCs), haematopoietic stem cells (HSCs), endothelial progenitor cells/circulating endothelial cells (EPCs/CECs) and tissue‐committed stem cells (TCSCs)] in heart failure (HF) patients at different stage of pathology and correlated it with plasmatic levels of proangiogenic cytokines. Peripheral blood level of SCs were analysed in 97 HF patients (24 in NYHA class I, 41 in class II, 17 in class III and 15 in class IV) and in 23 healthy controls. Plasmatic levels of PDGF‐BB, bFGF, HGF, vascular endothelial growth factor (VEGF), SDF‐1α, TNF‐α and NTproBNP were also measured. Compared with healthy individuals, MSC, and in particular the sub‐classes CD45−CD34−CD90+, CD45−CD34−CD105+ and CD45−CD34−CXCR4+ were significantly enhanced in NYHA class IV patients (16.8‐, 6.4‐ and 2.7‐fold, respectively). Level of CD45−CD34−CD90+CXCR4+cells progressively increased from class II to class IV (fold increases compared with controls: 8.5, 12 and 21.5, respectively). A significant involvement of CXCR4+ subpopulation of HSC (CD45+CD34+CD90+CXCR4+, 1.4 versus 13.3 cells/μl in controls and NYHA class III patients, respectively) and TCSC (CD45−CD34+CXCR4+, 1.5 cells/ μl in controls versus 12.4 and 28.6 cells/μl in NYHA classes II and IV, respectively) were also observed. All tested cytokines were enhanced in HF patients. In particular, for PDGF‐BB and SDF‐1α we studied specific ligand/receptors pairs. Interestingly, the first one positively correlated with TCSCs expressing PDGFR (r = 0.52, P = 0.001), whereas the second one correlated with TCSCs (r = 0.34, P = 0.005) and with MSCs CD90+ expressing CXCR4 (r = 0.39, P = 0.001). HF is characterized by the increase in the circulating levels of different MSC, HSC, EPC and TCSC subsets. Both the entity and kinetic of this process varied in distinct cell subsets. Specifically, differently from HSCs and EPCs/CECs, MSCs and TCSCs significantly increased with the progression of the disease, suggesting a possible distinct role of these cells in the pathophysiology of HF. |
| doi_str_mv | 10.1111/j.1582-4934.2010.01195.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4373363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>877406099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5025-2478751e090c2d351bf9fe63f35d76c35f2f33b7b1a279a58184c53d5751306d3</originalsourceid><addsrcrecordid>eNqNUctOAyEUJUbj-xcMiQtXrcAdBtiYmPqopupGF64InWFamulMhRkffy-jtT5WsuGG8-CeHIQwJX0az_GsT7lkvURB0mckvhJKFe-_rqHtFbC-nKkEuYV2QpgRAikFtYm2GCVMgYBtdDZwPmtL07hqgkNj5zizZYmfjX_DL66Z4tvH4WkEzMRiV-GpNb7BhXFl6y1eRJmtmrCHNgpTBru_vHfRw8X5_WDYG91dXg1OR72ME8Z7LBFScGqJIhnLgdNxoQqbQgE8F2kGvGAFwFiMqWFCGS6pTDIOOY8iIGkOu-jk03fRjuc2z-Lf3pR64d087qtr4_RvpHJTPamfdRKzQgrR4Ghp4Oun1oZGz13oApvK1m3QUoiEpESpyDz8w5zVra9iOg1EcMUlJDSy5Ccr83UI3harXSjRXVN6prsSdFeI7prSH03p1yg9-JllJfyq5jvsiyvt27-N9fXg5qYb4R0mX6DU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3075958341</pqid></control><display><type>article</type><title>Circulating stem cell vary with NYHA stage in heart failure patients</title><source>Wiley-Blackwell Open Access Titles</source><creator>Fortini, Cinzia ; Toffoletto, Barbara ; Fucili, Alessandro ; Puppato, Elisa ; Olivares, Adriana ; Beltrami, Antonio Paolo ; Fiorelli, Valeria ; Bergamin, Natascha ; Cesselli, Daniela ; Morelli, Cristina ; Francolini, Gloria ; Ferrari, Roberto ; Beltrami, Carlo Alberto</creator><creatorcontrib>Fortini, Cinzia ; Toffoletto, Barbara ; Fucili, Alessandro ; Puppato, Elisa ; Olivares, Adriana ; Beltrami, Antonio Paolo ; Fiorelli, Valeria ; Bergamin, Natascha ; Cesselli, Daniela ; Morelli, Cristina ; Francolini, Gloria ; Ferrari, Roberto ; Beltrami, Carlo Alberto</creatorcontrib><description>We have investigated the blood levels of sub‐classes of stem cells (SCs) [mesenchymal stem cells (MSCs), haematopoietic stem cells (HSCs), endothelial progenitor cells/circulating endothelial cells (EPCs/CECs) and tissue‐committed stem cells (TCSCs)] in heart failure (HF) patients at different stage of pathology and correlated it with plasmatic levels of proangiogenic cytokines. Peripheral blood level of SCs were analysed in 97 HF patients (24 in NYHA class I, 41 in class II, 17 in class III and 15 in class IV) and in 23 healthy controls. Plasmatic levels of PDGF‐BB, bFGF, HGF, vascular endothelial growth factor (VEGF), SDF‐1α, TNF‐α and NTproBNP were also measured. Compared with healthy individuals, MSC, and in particular the sub‐classes CD45−CD34−CD90+, CD45−CD34−CD105+ and CD45−CD34−CXCR4+ were significantly enhanced in NYHA class IV patients (16.8‐, 6.4‐ and 2.7‐fold, respectively). Level of CD45−CD34−CD90+CXCR4+cells progressively increased from class II to class IV (fold increases compared with controls: 8.5, 12 and 21.5, respectively). A significant involvement of CXCR4+ subpopulation of HSC (CD45+CD34+CD90+CXCR4+, 1.4 versus 13.3 cells/μl in controls and NYHA class III patients, respectively) and TCSC (CD45−CD34+CXCR4+, 1.5 cells/ μl in controls versus 12.4 and 28.6 cells/μl in NYHA classes II and IV, respectively) were also observed. All tested cytokines were enhanced in HF patients. In particular, for PDGF‐BB and SDF‐1α we studied specific ligand/receptors pairs. Interestingly, the first one positively correlated with TCSCs expressing PDGFR (r = 0.52, P = 0.001), whereas the second one correlated with TCSCs (r = 0.34, P = 0.005) and with MSCs CD90+ expressing CXCR4 (r = 0.39, P = 0.001). HF is characterized by the increase in the circulating levels of different MSC, HSC, EPC and TCSC subsets. Both the entity and kinetic of this process varied in distinct cell subsets. Specifically, differently from HSCs and EPCs/CECs, MSCs and TCSCs significantly increased with the progression of the disease, suggesting a possible distinct role of these cells in the pathophysiology of HF.</description><identifier>ISSN: 1582-1838</identifier><identifier>EISSN: 1582-4934</identifier><identifier>DOI: 10.1111/j.1582-4934.2010.01195.x</identifier><identifier>PMID: 21029373</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Analysis of Variance ; Antigens, CD - blood ; Blood levels ; Bone marrow ; CD105 antigen ; CD34 antigen ; CD45 antigen ; CD90 antigen ; Chemokine CXCL12 - blood ; Congestive heart failure ; CXCR4 protein ; Cytokines ; Cytokines - blood ; Ejection fraction ; Endothelial cells ; Endothelial Cells - metabolism ; endothelial progenitor cells ; Enzyme-Linked Immunosorbent Assay ; Enzymes ; Female ; Fibroblast growth factor 2 ; Fibroblast Growth Factor 2 - blood ; haematopoietic stem cells ; Heart failure ; Heart Failure - blood ; Heart Failure - classification ; Heart Failure - pathology ; Hematopoietic stem cells ; Hematopoietic Stem Cells - metabolism ; Hepatocyte Growth Factor - blood ; Humans ; Hypertension ; Immunoassay ; Ischemia ; Male ; Mesenchymal stem cells ; Mesenchymal Stromal Cells - metabolism ; Middle Aged ; myocardial repair ; Peripheral blood ; Plasma ; Platelet-derived growth factor ; Platelet-Derived Growth Factor - metabolism ; Platelet-derived growth factor BB ; Progenitor cells ; Proto-Oncogene Proteins c-sis ; Receptors, CXCR4 - blood ; Recruitment ; Risk factors ; Severity of Illness Index ; Stem cells ; Stem Cells - metabolism ; Thy-1 Antigens - blood ; Tumor Necrosis Factor-alpha - blood ; Tumor necrosis factor-α ; Variance analysis ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - blood</subject><ispartof>Journal of cellular and molecular medicine, 2011-08, Vol.15 (8), p.1726-1736</ispartof><rights>2011 The Authors Journal compilation © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd</rights><rights>2011 The Authors Journal compilation © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.</rights><rights>2011. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2011 The Authors Journal compilation © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5025-2478751e090c2d351bf9fe63f35d76c35f2f33b7b1a279a58184c53d5751306d3</citedby><cites>FETCH-LOGICAL-c5025-2478751e090c2d351bf9fe63f35d76c35f2f33b7b1a279a58184c53d5751306d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373363/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373363/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,1419,11569,27931,27932,45581,45582,46059,46483,53798,53800</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1582-4934.2010.01195.x$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21029373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fortini, Cinzia</creatorcontrib><creatorcontrib>Toffoletto, Barbara</creatorcontrib><creatorcontrib>Fucili, Alessandro</creatorcontrib><creatorcontrib>Puppato, Elisa</creatorcontrib><creatorcontrib>Olivares, Adriana</creatorcontrib><creatorcontrib>Beltrami, Antonio Paolo</creatorcontrib><creatorcontrib>Fiorelli, Valeria</creatorcontrib><creatorcontrib>Bergamin, Natascha</creatorcontrib><creatorcontrib>Cesselli, Daniela</creatorcontrib><creatorcontrib>Morelli, Cristina</creatorcontrib><creatorcontrib>Francolini, Gloria</creatorcontrib><creatorcontrib>Ferrari, Roberto</creatorcontrib><creatorcontrib>Beltrami, Carlo Alberto</creatorcontrib><title>Circulating stem cell vary with NYHA stage in heart failure patients</title><title>Journal of cellular and molecular medicine</title><addtitle>J Cell Mol Med</addtitle><description>We have investigated the blood levels of sub‐classes of stem cells (SCs) [mesenchymal stem cells (MSCs), haematopoietic stem cells (HSCs), endothelial progenitor cells/circulating endothelial cells (EPCs/CECs) and tissue‐committed stem cells (TCSCs)] in heart failure (HF) patients at different stage of pathology and correlated it with plasmatic levels of proangiogenic cytokines. Peripheral blood level of SCs were analysed in 97 HF patients (24 in NYHA class I, 41 in class II, 17 in class III and 15 in class IV) and in 23 healthy controls. Plasmatic levels of PDGF‐BB, bFGF, HGF, vascular endothelial growth factor (VEGF), SDF‐1α, TNF‐α and NTproBNP were also measured. Compared with healthy individuals, MSC, and in particular the sub‐classes CD45−CD34−CD90+, CD45−CD34−CD105+ and CD45−CD34−CXCR4+ were significantly enhanced in NYHA class IV patients (16.8‐, 6.4‐ and 2.7‐fold, respectively). Level of CD45−CD34−CD90+CXCR4+cells progressively increased from class II to class IV (fold increases compared with controls: 8.5, 12 and 21.5, respectively). A significant involvement of CXCR4+ subpopulation of HSC (CD45+CD34+CD90+CXCR4+, 1.4 versus 13.3 cells/μl in controls and NYHA class III patients, respectively) and TCSC (CD45−CD34+CXCR4+, 1.5 cells/ μl in controls versus 12.4 and 28.6 cells/μl in NYHA classes II and IV, respectively) were also observed. All tested cytokines were enhanced in HF patients. In particular, for PDGF‐BB and SDF‐1α we studied specific ligand/receptors pairs. Interestingly, the first one positively correlated with TCSCs expressing PDGFR (r = 0.52, P = 0.001), whereas the second one correlated with TCSCs (r = 0.34, P = 0.005) and with MSCs CD90+ expressing CXCR4 (r = 0.39, P = 0.001). HF is characterized by the increase in the circulating levels of different MSC, HSC, EPC and TCSC subsets. Both the entity and kinetic of this process varied in distinct cell subsets. Specifically, differently from HSCs and EPCs/CECs, MSCs and TCSCs significantly increased with the progression of the disease, suggesting a possible distinct role of these cells in the pathophysiology of HF.</description><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Antigens, CD - blood</subject><subject>Blood levels</subject><subject>Bone marrow</subject><subject>CD105 antigen</subject><subject>CD34 antigen</subject><subject>CD45 antigen</subject><subject>CD90 antigen</subject><subject>Chemokine CXCL12 - blood</subject><subject>Congestive heart failure</subject><subject>CXCR4 protein</subject><subject>Cytokines</subject><subject>Cytokines - blood</subject><subject>Ejection fraction</subject><subject>Endothelial cells</subject><subject>Endothelial Cells - metabolism</subject><subject>endothelial progenitor cells</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Enzymes</subject><subject>Female</subject><subject>Fibroblast growth factor 2</subject><subject>Fibroblast Growth Factor 2 - blood</subject><subject>haematopoietic stem cells</subject><subject>Heart failure</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - classification</subject><subject>Heart Failure - pathology</subject><subject>Hematopoietic stem cells</subject><subject>Hematopoietic Stem Cells - metabolism</subject><subject>Hepatocyte Growth Factor - blood</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Immunoassay</subject><subject>Ischemia</subject><subject>Male</subject><subject>Mesenchymal stem cells</subject><subject>Mesenchymal Stromal Cells - metabolism</subject><subject>Middle Aged</subject><subject>myocardial repair</subject><subject>Peripheral blood</subject><subject>Plasma</subject><subject>Platelet-derived growth factor</subject><subject>Platelet-Derived Growth Factor - metabolism</subject><subject>Platelet-derived growth factor BB</subject><subject>Progenitor cells</subject><subject>Proto-Oncogene Proteins c-sis</subject><subject>Receptors, CXCR4 - blood</subject><subject>Recruitment</subject><subject>Risk factors</subject><subject>Severity of Illness Index</subject><subject>Stem cells</subject><subject>Stem Cells - metabolism</subject><subject>Thy-1 Antigens - blood</subject><subject>Tumor Necrosis Factor-alpha - blood</subject><subject>Tumor necrosis factor-α</subject><subject>Variance analysis</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><issn>1582-1838</issn><issn>1582-4934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNUctOAyEUJUbj-xcMiQtXrcAdBtiYmPqopupGF64InWFamulMhRkffy-jtT5WsuGG8-CeHIQwJX0az_GsT7lkvURB0mckvhJKFe-_rqHtFbC-nKkEuYV2QpgRAikFtYm2GCVMgYBtdDZwPmtL07hqgkNj5zizZYmfjX_DL66Z4tvH4WkEzMRiV-GpNb7BhXFl6y1eRJmtmrCHNgpTBru_vHfRw8X5_WDYG91dXg1OR72ME8Z7LBFScGqJIhnLgdNxoQqbQgE8F2kGvGAFwFiMqWFCGS6pTDIOOY8iIGkOu-jk03fRjuc2z-Lf3pR64d087qtr4_RvpHJTPamfdRKzQgrR4Ghp4Oun1oZGz13oApvK1m3QUoiEpESpyDz8w5zVra9iOg1EcMUlJDSy5Ccr83UI3harXSjRXVN6prsSdFeI7prSH03p1yg9-JllJfyq5jvsiyvt27-N9fXg5qYb4R0mX6DU</recordid><startdate>201108</startdate><enddate>201108</enddate><creator>Fortini, Cinzia</creator><creator>Toffoletto, Barbara</creator><creator>Fucili, Alessandro</creator><creator>Puppato, Elisa</creator><creator>Olivares, Adriana</creator><creator>Beltrami, Antonio Paolo</creator><creator>Fiorelli, Valeria</creator><creator>Bergamin, Natascha</creator><creator>Cesselli, Daniela</creator><creator>Morelli, Cristina</creator><creator>Francolini, Gloria</creator><creator>Ferrari, Roberto</creator><creator>Beltrami, Carlo Alberto</creator><general>Blackwell Publishing Ltd</general><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201108</creationdate><title>Circulating stem cell vary with NYHA stage in heart failure patients</title><author>Fortini, Cinzia ; Toffoletto, Barbara ; Fucili, Alessandro ; Puppato, Elisa ; Olivares, Adriana ; Beltrami, Antonio Paolo ; Fiorelli, Valeria ; Bergamin, Natascha ; Cesselli, Daniela ; Morelli, Cristina ; Francolini, Gloria ; Ferrari, Roberto ; Beltrami, Carlo Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5025-2478751e090c2d351bf9fe63f35d76c35f2f33b7b1a279a58184c53d5751306d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Antigens, CD - blood</topic><topic>Blood levels</topic><topic>Bone marrow</topic><topic>CD105 antigen</topic><topic>CD34 antigen</topic><topic>CD45 antigen</topic><topic>CD90 antigen</topic><topic>Chemokine CXCL12 - blood</topic><topic>Congestive heart failure</topic><topic>CXCR4 protein</topic><topic>Cytokines</topic><topic>Cytokines - blood</topic><topic>Ejection fraction</topic><topic>Endothelial cells</topic><topic>Endothelial Cells - metabolism</topic><topic>endothelial progenitor cells</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Enzymes</topic><topic>Female</topic><topic>Fibroblast growth factor 2</topic><topic>Fibroblast Growth Factor 2 - blood</topic><topic>haematopoietic stem cells</topic><topic>Heart failure</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - classification</topic><topic>Heart Failure - pathology</topic><topic>Hematopoietic stem cells</topic><topic>Hematopoietic Stem Cells - metabolism</topic><topic>Hepatocyte Growth Factor - blood</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Immunoassay</topic><topic>Ischemia</topic><topic>Male</topic><topic>Mesenchymal stem cells</topic><topic>Mesenchymal Stromal Cells - metabolism</topic><topic>Middle Aged</topic><topic>myocardial repair</topic><topic>Peripheral blood</topic><topic>Plasma</topic><topic>Platelet-derived growth factor</topic><topic>Platelet-Derived Growth Factor - metabolism</topic><topic>Platelet-derived growth factor BB</topic><topic>Progenitor cells</topic><topic>Proto-Oncogene Proteins c-sis</topic><topic>Receptors, CXCR4 - blood</topic><topic>Recruitment</topic><topic>Risk factors</topic><topic>Severity of Illness Index</topic><topic>Stem cells</topic><topic>Stem Cells - metabolism</topic><topic>Thy-1 Antigens - blood</topic><topic>Tumor Necrosis Factor-alpha - blood</topic><topic>Tumor necrosis factor-α</topic><topic>Variance analysis</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fortini, Cinzia</creatorcontrib><creatorcontrib>Toffoletto, Barbara</creatorcontrib><creatorcontrib>Fucili, Alessandro</creatorcontrib><creatorcontrib>Puppato, Elisa</creatorcontrib><creatorcontrib>Olivares, Adriana</creatorcontrib><creatorcontrib>Beltrami, Antonio Paolo</creatorcontrib><creatorcontrib>Fiorelli, Valeria</creatorcontrib><creatorcontrib>Bergamin, Natascha</creatorcontrib><creatorcontrib>Cesselli, Daniela</creatorcontrib><creatorcontrib>Morelli, Cristina</creatorcontrib><creatorcontrib>Francolini, Gloria</creatorcontrib><creatorcontrib>Ferrari, Roberto</creatorcontrib><creatorcontrib>Beltrami, Carlo Alberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cellular and molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Fortini, Cinzia</au><au>Toffoletto, Barbara</au><au>Fucili, Alessandro</au><au>Puppato, Elisa</au><au>Olivares, Adriana</au><au>Beltrami, Antonio Paolo</au><au>Fiorelli, Valeria</au><au>Bergamin, Natascha</au><au>Cesselli, Daniela</au><au>Morelli, Cristina</au><au>Francolini, Gloria</au><au>Ferrari, Roberto</au><au>Beltrami, Carlo Alberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating stem cell vary with NYHA stage in heart failure patients</atitle><jtitle>Journal of cellular and molecular medicine</jtitle><addtitle>J Cell Mol Med</addtitle><date>2011-08</date><risdate>2011</risdate><volume>15</volume><issue>8</issue><spage>1726</spage><epage>1736</epage><pages>1726-1736</pages><issn>1582-1838</issn><eissn>1582-4934</eissn><abstract>We have investigated the blood levels of sub‐classes of stem cells (SCs) [mesenchymal stem cells (MSCs), haematopoietic stem cells (HSCs), endothelial progenitor cells/circulating endothelial cells (EPCs/CECs) and tissue‐committed stem cells (TCSCs)] in heart failure (HF) patients at different stage of pathology and correlated it with plasmatic levels of proangiogenic cytokines. Peripheral blood level of SCs were analysed in 97 HF patients (24 in NYHA class I, 41 in class II, 17 in class III and 15 in class IV) and in 23 healthy controls. Plasmatic levels of PDGF‐BB, bFGF, HGF, vascular endothelial growth factor (VEGF), SDF‐1α, TNF‐α and NTproBNP were also measured. Compared with healthy individuals, MSC, and in particular the sub‐classes CD45−CD34−CD90+, CD45−CD34−CD105+ and CD45−CD34−CXCR4+ were significantly enhanced in NYHA class IV patients (16.8‐, 6.4‐ and 2.7‐fold, respectively). Level of CD45−CD34−CD90+CXCR4+cells progressively increased from class II to class IV (fold increases compared with controls: 8.5, 12 and 21.5, respectively). A significant involvement of CXCR4+ subpopulation of HSC (CD45+CD34+CD90+CXCR4+, 1.4 versus 13.3 cells/μl in controls and NYHA class III patients, respectively) and TCSC (CD45−CD34+CXCR4+, 1.5 cells/ μl in controls versus 12.4 and 28.6 cells/μl in NYHA classes II and IV, respectively) were also observed. All tested cytokines were enhanced in HF patients. In particular, for PDGF‐BB and SDF‐1α we studied specific ligand/receptors pairs. Interestingly, the first one positively correlated with TCSCs expressing PDGFR (r = 0.52, P = 0.001), whereas the second one correlated with TCSCs (r = 0.34, P = 0.005) and with MSCs CD90+ expressing CXCR4 (r = 0.39, P = 0.001). HF is characterized by the increase in the circulating levels of different MSC, HSC, EPC and TCSC subsets. Both the entity and kinetic of this process varied in distinct cell subsets. Specifically, differently from HSCs and EPCs/CECs, MSCs and TCSCs significantly increased with the progression of the disease, suggesting a possible distinct role of these cells in the pathophysiology of HF.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21029373</pmid><doi>10.1111/j.1582-4934.2010.01195.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1582-1838 |
| ispartof | Journal of cellular and molecular medicine, 2011-08, Vol.15 (8), p.1726-1736 |
| issn | 1582-1838 1582-4934 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4373363 |
| source | Wiley-Blackwell Open Access Titles |
| subjects | Aged Analysis of Variance Antigens, CD - blood Blood levels Bone marrow CD105 antigen CD34 antigen CD45 antigen CD90 antigen Chemokine CXCL12 - blood Congestive heart failure CXCR4 protein Cytokines Cytokines - blood Ejection fraction Endothelial cells Endothelial Cells - metabolism endothelial progenitor cells Enzyme-Linked Immunosorbent Assay Enzymes Female Fibroblast growth factor 2 Fibroblast Growth Factor 2 - blood haematopoietic stem cells Heart failure Heart Failure - blood Heart Failure - classification Heart Failure - pathology Hematopoietic stem cells Hematopoietic Stem Cells - metabolism Hepatocyte Growth Factor - blood Humans Hypertension Immunoassay Ischemia Male Mesenchymal stem cells Mesenchymal Stromal Cells - metabolism Middle Aged myocardial repair Peripheral blood Plasma Platelet-derived growth factor Platelet-Derived Growth Factor - metabolism Platelet-derived growth factor BB Progenitor cells Proto-Oncogene Proteins c-sis Receptors, CXCR4 - blood Recruitment Risk factors Severity of Illness Index Stem cells Stem Cells - metabolism Thy-1 Antigens - blood Tumor Necrosis Factor-alpha - blood Tumor necrosis factor-α Variance analysis Vascular endothelial growth factor Vascular Endothelial Growth Factor A - blood |
| title | Circulating stem cell vary with NYHA stage in heart failure patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T23%3A07%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20stem%20cell%20vary%20with%20NYHA%20stage%20in%20heart%20failure%20patients&rft.jtitle=Journal%20of%20cellular%20and%20molecular%20medicine&rft.au=Fortini,%20Cinzia&rft.date=2011-08&rft.volume=15&rft.issue=8&rft.spage=1726&rft.epage=1736&rft.pages=1726-1736&rft.issn=1582-1838&rft.eissn=1582-4934&rft_id=info:doi/10.1111/j.1582-4934.2010.01195.x&rft_dat=%3Cproquest_24P%3E877406099%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3075958341&rft_id=info:pmid/21029373&rfr_iscdi=true |